Quantifying hypertension in patients with cancer treated with sorafenib

Lancet Oncol. 2008 Feb;9(2):86-7. doi: 10.1016/S1470-2045(08)70009-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Benzenesulfonates / adverse effects*
  • Humans
  • Hypertension / chemically induced
  • Hypertension / classification
  • Hypertension / diagnosis*
  • Neoplasms / drug therapy
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / adverse effects*
  • Sorafenib
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Sorafenib